SEC Form 6-K filed by Compugen Ltd.
$CGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2024
Commission File Number 000-30902
COMPUGEN LTD.
(Translation of registrant’s name into English)
|
|
|
26 Harokmim Street
|
|
Holon 5885849, Israel
|
|
(Address of Principal Executive Offices)
|
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Compugen Ltd.
On March 5, 2024, Compugen Ltd. (the “Company”) issued a press release reporting the Company’s fourth quarter and full year 2023 results (the “Press Release”), a copy of which is furnished as Exhibit 99.1 to this Report on Form 6-K.
With the exception of the quotes attributable to Anat Cohen-Dayag, Ph.D., information contained in the Press Release is hereby incorporated by reference into the Company’s Registration Statement on
Form F-3, File No. 333-270985.
|
Exhibit
|
|
|
|
Number
|
Description of Exhibit
|
|
|
|
|
|
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
COMPUGEN LTD.
|
|
|
|
|
|||
|
Date: March 5, 2024
|
By:
|
/s/ Eran Ben Dor
|
|
|
|
|
Eran Ben Dor
|
|
|
|
|
General Counsel
|
|